-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the...
First FGF21 analog to enter Phase 3 developmentSAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a...
Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor...
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical DevelopmentLA JOLLA, Calif.,...
PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its...
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also...
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression in autoimmunity models, supporting potential...
CTS Activities will Focus on Analytic Method Transfer, Manufacturing of R&D Engineering Batches, and Stability Studies to Support Planned Clinical...
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi...
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 NMD1343 is a novel small molecule inhibitor of...
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
Recruitment to Resume Imminently Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, May 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD)...
LEXINGTON, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
– Funds will support advancement of two KRAS inhibitor programs into the clinic in 2024 –– Financing led by Avidity...
AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
PALO ALTO, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento...
Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the...
Figure 2 REDWOOD-HCM Cohort 4: Angina Symptoms Figure 1 REDWOOD-HCM Cohort 4: Kansas City Cardiomyopathy Questionnaire (KCCQ) Figure 4 REDWOOD-HCM...
Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy...